Evaluation of prescribing appropriateness and drug utilization of anti-tuberculosis drugs in pediatric pulmonary tuberculosis patients in Indonesia: A study in East Java

Authors

  • Noer N. Varhinna Faculty of Pharmacy, Universitas Surabaya, Surabaya, Indonesia
  • Fauna Herawati Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Surabaya, Surabaya, Indonesia https://orcid.org/0000-0002-8355-955X
  • Rika Yulia Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Surabaya, Surabaya, Indonesia
  • Nur P. Ayumuyas Department of Pharmacy, Haji General Hospital of East Java Province, Surabaya, Indonesia

DOI:

https://doi.org/10.52225/narra.v6i3.3154

Keywords:

Pediatric tuberculosis, anti-tuberculosis drugs, prescribing appropriateness, ATC/DDD, DU90%

Abstract

Pediatric tuberculosis (TB) remains an important public health problem in Indonesia. This study aimed to describe anti-tuberculosis drug utilization and evaluate prescribing appropriateness among pediatric pulmonary TB outpatients at an Indonesian hospital. This retrospective descriptive study reviewed medical records using the Anatomical Therapeutic Chemical/Defined Daily Dose (ATC/DDD) and Drug Utilization 90% (DU90%) methods at Haji General Hospital, East Java, Indonesia, during January–December 2025. Prescribing appropriateness was assessed against the 2024 Indonesian Handbook for the Management of Tuberculosis in Children and Adolescents. Among 76 patients, 56.58% were male, 65.79% were aged 1–4 years, and 40.79% weighed 8–11 kg. Treatment was documented during the intensive phase in 73 patients, the continuation phase in 66 patients, and both phases in 63 patients (82.89%). Isoniazid had the highest utilization in both phases (11,307.29 and 9,614.80 DDD/1,000 outpatient visits, respectively). The DU90% segment comprised isoniazid, rifampicin, and pyrazinamide during the intensive phase and isoniazid and rifampicin during the continuation phase. All patients received first-line regimens. Weight-based dosing was classified as inappropriate for rifampicin in 28/76 patients (36.84%), isoniazid and pyrazinamide in 41/76 patients each (53.95%), and ethambutol in 2/4 (50.00%). Treatment duration met the study criteria in 34/73 patients (46.58%) during the intensive phase and 23/66 (34.85%) during the continuation phase. These findings identified discrepancies in documented weight-based dosing and treatment duration that warrant prescription review and verification of longitudinal treatment records. Adult-based DDD values described standardized utilization and did not establish pediatric dose appropriateness. Incomplete treatment documentation limited interpretation of duration discrepancies and treatment completion.

Downloads

Download data is not yet available.

Downloads

Published

2026-11-18

How to Cite

Varhinna, N. N., Herawati, F., Yulia, R., & Ayumuyas, N. P. (2026). Evaluation of prescribing appropriateness and drug utilization of anti-tuberculosis drugs in pediatric pulmonary tuberculosis patients in Indonesia: A study in East Java. Narra J, 6(3), e3154. https://doi.org/10.52225/narra.v6i3.3154